Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized. In this po...
Gespeichert in:
| Veröffentlicht in: | PloS one 2024-09, Vol.19 (9), p.e0309810 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | e0309810 |
| container_title | PloS one |
| container_volume | 19 |
| creator | Wood, Mariah S Halmer, Nicole Bertolli, Jeanne Amsden, Laura B Nugent, Joshua R Lin, Jin-Mann S Rothrock, Gretchen Nadle, Joelle Chai, Shua J Cope, Jennifer R Champsi, Jamila H Yang, James Unger, Elizabeth R Skarbinski, Jacek |
| description | Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized.
In this population-based cross-sectional study, we enrolled a stratified random sample of 9,825 adult participants in the Kaiser Permanente Northern California (KPNC) integrated health system from July to October 2022 to assess overall ME/CFS-like illness prevalence and the proportion that were identified following COVID-19 illness. We used medical record and survey data to estimate the prevalence of ME/CFS-like illness based on self-reported symptoms congruent with the 2015 Institute of Medicine ME/CFS criteria. History of COVID-19 was based on a positive SARS-CoV-2 nucleic acid amplification test or ICD-10 diagnosis code in the medical record, or self-report of prior COVID-19 on a survey.
Of 2,745,374 adults in the eligible population, an estimated 45,892 (95% confidence interval [CI]: 32,869, 58,914) or 1.67% (CI 1.20%, 2.15%) had ME/CFS-like illness. Among those with ME/CFS-like illness, an estimated 14.12% (CI 3.64%, 24.6%) developed the illness after COVID-19. Among persons who had COVID-19, those with ME/CFS-like illness after COVID-19 were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021. All persons with ME/CFS-like illness had significant impairment in physical, mental, emotional, social, and occupational functioning compared to persons without ME/CFS-like illness.
In a large, integrated health system, 1.67% of adults had ME/CFS-like illness and 14.12% of all persons with ME/CFS-like illness developed it after COVID-19. Though COVID-19 did not substantially increase ME/CFS-like illness in the KPNC population during the study time period, ME/CFS-like illness nevertheless affects a notable portion of this population and is consistent with estimates of ME/CFS prevalence in other populations. Additional attention is needed to improve awareness, diagnosis, and treatment of ME/CFS. |
| doi_str_mv | 10.1371/journal.pone.0309810 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3106664852</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A809114751</galeid><sourcerecordid>A809114751</sourcerecordid><originalsourceid>FETCH-LOGICAL-c506t-2751abb3f67fe2d9b855e928533d17085adef89cd9a4366e52f1cdc8167e3c8b3</originalsourceid><addsrcrecordid>eNqNkkuL2zAUhU1p6Tzaf1BaQaG0C2ckK5blbkpIX4GBQB-zFYp8nWgqSx7JDuP--iqNZ0jKLIoWEtJ37r0cnSR5QfCE0IJcXLveW2kmrbMwwRSXnOBHySkpaZayDNPHB-eT5CyEa4xzyhl7mpzQMiszVpDT5PeiaaXqkKvRfHm1-JiSEjmLmkGatVYIrIJ2I41rBjC60-FCbbyz8aWWnV73gMJgK-8aSI3-BUgbYyEE1HrYSrNTv0czpLwLIQ2gOu3iyCj0fgvDs-RJLU2A5-N-nvz8_OnH_Gt6ufyymM8uU5Vj1qVZkRO5WtGaFTVkVbnieQ5lxnNKK1JgnssKal6qqpRTyhjkWU1UpThhBVDFV_Q8ebWv2xoXxGhbEJRgxtiU51kkPoxEv2qgUmA7L41ovW6kH4STWhy_WL0Ra7cVhEwJzqY0Vng7VvDupofQiUYHBcZIC67fNyso4YRH9PU_6MMjjdQ62ii0rV1srHZFxYzjMjaOtkRq8gAVVwWNVjEYtY73R4J3R4LIdHDbrWUfglh8__b_7PLqmH1zwG5Amm4TnOl3Hx6Oweke_JsJD_W9ywSLXa7v3BC7XIsx11H28vCH7kV3QaZ_ADkh8_A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3106664852</pqid></control><display><type>article</type><title>Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Wood, Mariah S ; Halmer, Nicole ; Bertolli, Jeanne ; Amsden, Laura B ; Nugent, Joshua R ; Lin, Jin-Mann S ; Rothrock, Gretchen ; Nadle, Joelle ; Chai, Shua J ; Cope, Jennifer R ; Champsi, Jamila H ; Yang, James ; Unger, Elizabeth R ; Skarbinski, Jacek</creator><creatorcontrib>Wood, Mariah S ; Halmer, Nicole ; Bertolli, Jeanne ; Amsden, Laura B ; Nugent, Joshua R ; Lin, Jin-Mann S ; Rothrock, Gretchen ; Nadle, Joelle ; Chai, Shua J ; Cope, Jennifer R ; Champsi, Jamila H ; Yang, James ; Unger, Elizabeth R ; Skarbinski, Jacek ; for STOP-ME/CFS and COVID-SELECT</creatorcontrib><description>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized.
In this population-based cross-sectional study, we enrolled a stratified random sample of 9,825 adult participants in the Kaiser Permanente Northern California (KPNC) integrated health system from July to October 2022 to assess overall ME/CFS-like illness prevalence and the proportion that were identified following COVID-19 illness. We used medical record and survey data to estimate the prevalence of ME/CFS-like illness based on self-reported symptoms congruent with the 2015 Institute of Medicine ME/CFS criteria. History of COVID-19 was based on a positive SARS-CoV-2 nucleic acid amplification test or ICD-10 diagnosis code in the medical record, or self-report of prior COVID-19 on a survey.
Of 2,745,374 adults in the eligible population, an estimated 45,892 (95% confidence interval [CI]: 32,869, 58,914) or 1.67% (CI 1.20%, 2.15%) had ME/CFS-like illness. Among those with ME/CFS-like illness, an estimated 14.12% (CI 3.64%, 24.6%) developed the illness after COVID-19. Among persons who had COVID-19, those with ME/CFS-like illness after COVID-19 were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021. All persons with ME/CFS-like illness had significant impairment in physical, mental, emotional, social, and occupational functioning compared to persons without ME/CFS-like illness.
In a large, integrated health system, 1.67% of adults had ME/CFS-like illness and 14.12% of all persons with ME/CFS-like illness developed it after COVID-19. Though COVID-19 did not substantially increase ME/CFS-like illness in the KPNC population during the study time period, ME/CFS-like illness nevertheless affects a notable portion of this population and is consistent with estimates of ME/CFS prevalence in other populations. Additional attention is needed to improve awareness, diagnosis, and treatment of ME/CFS.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0309810</identifier><identifier>PMID: 39292671</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Adults ; Aged ; Biology and Life Sciences ; California ; California - epidemiology ; Care and treatment ; Chronic fatigue syndrome ; Confidence intervals ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; Cross-Sectional Studies ; Development and progression ; Diagnosis ; Disease control ; Diseases ; Electronic health records ; Encephalomyelitis ; Epidemics ; Ethnicity ; Fatigue ; Fatigue Syndrome, Chronic - epidemiology ; Fatigue Syndrome, Chronic - virology ; Female ; Health aspects ; Health maintenance organizations ; Health surveillance ; Humans ; Illnesses ; Infections ; Male ; Medical records ; Medical research ; Medicine and Health Sciences ; Medicine, Experimental ; Middle Aged ; Nucleic acids ; Pandemics ; Population studies ; Prevalence ; Research and Analysis Methods ; Respiratory diseases ; SARS-CoV-2 - isolation & purification ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Surveys ; Surveys and Questionnaires ; Viral diseases ; Young Adult</subject><ispartof>PloS one, 2024-09, Vol.19 (9), p.e0309810</ispartof><rights>Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication: https://creativecommons.org/publicdomain/zero/1.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c506t-2751abb3f67fe2d9b855e928533d17085adef89cd9a4366e52f1cdc8167e3c8b3</cites><orcidid>0000-0001-8286-6593 ; 0000-0003-1630-5733</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410243/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410243/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39292671$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wood, Mariah S</creatorcontrib><creatorcontrib>Halmer, Nicole</creatorcontrib><creatorcontrib>Bertolli, Jeanne</creatorcontrib><creatorcontrib>Amsden, Laura B</creatorcontrib><creatorcontrib>Nugent, Joshua R</creatorcontrib><creatorcontrib>Lin, Jin-Mann S</creatorcontrib><creatorcontrib>Rothrock, Gretchen</creatorcontrib><creatorcontrib>Nadle, Joelle</creatorcontrib><creatorcontrib>Chai, Shua J</creatorcontrib><creatorcontrib>Cope, Jennifer R</creatorcontrib><creatorcontrib>Champsi, Jamila H</creatorcontrib><creatorcontrib>Yang, James</creatorcontrib><creatorcontrib>Unger, Elizabeth R</creatorcontrib><creatorcontrib>Skarbinski, Jacek</creatorcontrib><creatorcontrib>for STOP-ME/CFS and COVID-SELECT</creatorcontrib><title>Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized.
In this population-based cross-sectional study, we enrolled a stratified random sample of 9,825 adult participants in the Kaiser Permanente Northern California (KPNC) integrated health system from July to October 2022 to assess overall ME/CFS-like illness prevalence and the proportion that were identified following COVID-19 illness. We used medical record and survey data to estimate the prevalence of ME/CFS-like illness based on self-reported symptoms congruent with the 2015 Institute of Medicine ME/CFS criteria. History of COVID-19 was based on a positive SARS-CoV-2 nucleic acid amplification test or ICD-10 diagnosis code in the medical record, or self-report of prior COVID-19 on a survey.
Of 2,745,374 adults in the eligible population, an estimated 45,892 (95% confidence interval [CI]: 32,869, 58,914) or 1.67% (CI 1.20%, 2.15%) had ME/CFS-like illness. Among those with ME/CFS-like illness, an estimated 14.12% (CI 3.64%, 24.6%) developed the illness after COVID-19. Among persons who had COVID-19, those with ME/CFS-like illness after COVID-19 were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021. All persons with ME/CFS-like illness had significant impairment in physical, mental, emotional, social, and occupational functioning compared to persons without ME/CFS-like illness.
In a large, integrated health system, 1.67% of adults had ME/CFS-like illness and 14.12% of all persons with ME/CFS-like illness developed it after COVID-19. Though COVID-19 did not substantially increase ME/CFS-like illness in the KPNC population during the study time period, ME/CFS-like illness nevertheless affects a notable portion of this population and is consistent with estimates of ME/CFS prevalence in other populations. Additional attention is needed to improve awareness, diagnosis, and treatment of ME/CFS.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Biology and Life Sciences</subject><subject>California</subject><subject>California - epidemiology</subject><subject>Care and treatment</subject><subject>Chronic fatigue syndrome</subject><subject>Confidence intervals</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>Cross-Sectional Studies</subject><subject>Development and progression</subject><subject>Diagnosis</subject><subject>Disease control</subject><subject>Diseases</subject><subject>Electronic health records</subject><subject>Encephalomyelitis</subject><subject>Epidemics</subject><subject>Ethnicity</subject><subject>Fatigue</subject><subject>Fatigue Syndrome, Chronic - epidemiology</subject><subject>Fatigue Syndrome, Chronic - virology</subject><subject>Female</subject><subject>Health aspects</subject><subject>Health maintenance organizations</subject><subject>Health surveillance</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Infections</subject><subject>Male</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Medicine and Health Sciences</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Nucleic acids</subject><subject>Pandemics</subject><subject>Population studies</subject><subject>Prevalence</subject><subject>Research and Analysis Methods</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2 - isolation & purification</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Surveys</subject><subject>Surveys and Questionnaires</subject><subject>Viral diseases</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkkuL2zAUhU1p6Tzaf1BaQaG0C2ckK5blbkpIX4GBQB-zFYp8nWgqSx7JDuP--iqNZ0jKLIoWEtJ37r0cnSR5QfCE0IJcXLveW2kmrbMwwRSXnOBHySkpaZayDNPHB-eT5CyEa4xzyhl7mpzQMiszVpDT5PeiaaXqkKvRfHm1-JiSEjmLmkGatVYIrIJ2I41rBjC60-FCbbyz8aWWnV73gMJgK-8aSI3-BUgbYyEE1HrYSrNTv0czpLwLIQ2gOu3iyCj0fgvDs-RJLU2A5-N-nvz8_OnH_Gt6ufyymM8uU5Vj1qVZkRO5WtGaFTVkVbnieQ5lxnNKK1JgnssKal6qqpRTyhjkWU1UpThhBVDFV_Q8ebWv2xoXxGhbEJRgxtiU51kkPoxEv2qgUmA7L41ovW6kH4STWhy_WL0Ra7cVhEwJzqY0Vng7VvDupofQiUYHBcZIC67fNyso4YRH9PU_6MMjjdQ62ii0rV1srHZFxYzjMjaOtkRq8gAVVwWNVjEYtY73R4J3R4LIdHDbrWUfglh8__b_7PLqmH1zwG5Amm4TnOl3Hx6Oweke_JsJD_W9ywSLXa7v3BC7XIsx11H28vCH7kV3QaZ_ADkh8_A</recordid><startdate>20240918</startdate><enddate>20240918</enddate><creator>Wood, Mariah S</creator><creator>Halmer, Nicole</creator><creator>Bertolli, Jeanne</creator><creator>Amsden, Laura B</creator><creator>Nugent, Joshua R</creator><creator>Lin, Jin-Mann S</creator><creator>Rothrock, Gretchen</creator><creator>Nadle, Joelle</creator><creator>Chai, Shua J</creator><creator>Cope, Jennifer R</creator><creator>Champsi, Jamila H</creator><creator>Yang, James</creator><creator>Unger, Elizabeth R</creator><creator>Skarbinski, Jacek</creator><general>Public Library of Science</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8286-6593</orcidid><orcidid>https://orcid.org/0000-0003-1630-5733</orcidid></search><sort><creationdate>20240918</creationdate><title>Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey</title><author>Wood, Mariah S ; Halmer, Nicole ; Bertolli, Jeanne ; Amsden, Laura B ; Nugent, Joshua R ; Lin, Jin-Mann S ; Rothrock, Gretchen ; Nadle, Joelle ; Chai, Shua J ; Cope, Jennifer R ; Champsi, Jamila H ; Yang, James ; Unger, Elizabeth R ; Skarbinski, Jacek</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c506t-2751abb3f67fe2d9b855e928533d17085adef89cd9a4366e52f1cdc8167e3c8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Biology and Life Sciences</topic><topic>California</topic><topic>California - epidemiology</topic><topic>Care and treatment</topic><topic>Chronic fatigue syndrome</topic><topic>Confidence intervals</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>Cross-Sectional Studies</topic><topic>Development and progression</topic><topic>Diagnosis</topic><topic>Disease control</topic><topic>Diseases</topic><topic>Electronic health records</topic><topic>Encephalomyelitis</topic><topic>Epidemics</topic><topic>Ethnicity</topic><topic>Fatigue</topic><topic>Fatigue Syndrome, Chronic - epidemiology</topic><topic>Fatigue Syndrome, Chronic - virology</topic><topic>Female</topic><topic>Health aspects</topic><topic>Health maintenance organizations</topic><topic>Health surveillance</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Infections</topic><topic>Male</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Medicine and Health Sciences</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Nucleic acids</topic><topic>Pandemics</topic><topic>Population studies</topic><topic>Prevalence</topic><topic>Research and Analysis Methods</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2 - isolation & purification</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Surveys</topic><topic>Surveys and Questionnaires</topic><topic>Viral diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wood, Mariah S</creatorcontrib><creatorcontrib>Halmer, Nicole</creatorcontrib><creatorcontrib>Bertolli, Jeanne</creatorcontrib><creatorcontrib>Amsden, Laura B</creatorcontrib><creatorcontrib>Nugent, Joshua R</creatorcontrib><creatorcontrib>Lin, Jin-Mann S</creatorcontrib><creatorcontrib>Rothrock, Gretchen</creatorcontrib><creatorcontrib>Nadle, Joelle</creatorcontrib><creatorcontrib>Chai, Shua J</creatorcontrib><creatorcontrib>Cope, Jennifer R</creatorcontrib><creatorcontrib>Champsi, Jamila H</creatorcontrib><creatorcontrib>Yang, James</creatorcontrib><creatorcontrib>Unger, Elizabeth R</creatorcontrib><creatorcontrib>Skarbinski, Jacek</creatorcontrib><creatorcontrib>for STOP-ME/CFS and COVID-SELECT</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wood, Mariah S</au><au>Halmer, Nicole</au><au>Bertolli, Jeanne</au><au>Amsden, Laura B</au><au>Nugent, Joshua R</au><au>Lin, Jin-Mann S</au><au>Rothrock, Gretchen</au><au>Nadle, Joelle</au><au>Chai, Shua J</au><au>Cope, Jennifer R</au><au>Champsi, Jamila H</au><au>Yang, James</au><au>Unger, Elizabeth R</au><au>Skarbinski, Jacek</au><aucorp>for STOP-ME/CFS and COVID-SELECT</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2024-09-18</date><risdate>2024</risdate><volume>19</volume><issue>9</issue><spage>e0309810</spage><pages>e0309810-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic on ME/CFS prevalence is not well characterized.
In this population-based cross-sectional study, we enrolled a stratified random sample of 9,825 adult participants in the Kaiser Permanente Northern California (KPNC) integrated health system from July to October 2022 to assess overall ME/CFS-like illness prevalence and the proportion that were identified following COVID-19 illness. We used medical record and survey data to estimate the prevalence of ME/CFS-like illness based on self-reported symptoms congruent with the 2015 Institute of Medicine ME/CFS criteria. History of COVID-19 was based on a positive SARS-CoV-2 nucleic acid amplification test or ICD-10 diagnosis code in the medical record, or self-report of prior COVID-19 on a survey.
Of 2,745,374 adults in the eligible population, an estimated 45,892 (95% confidence interval [CI]: 32,869, 58,914) or 1.67% (CI 1.20%, 2.15%) had ME/CFS-like illness. Among those with ME/CFS-like illness, an estimated 14.12% (CI 3.64%, 24.6%) developed the illness after COVID-19. Among persons who had COVID-19, those with ME/CFS-like illness after COVID-19 were more likely to be unvaccinated and to have had COVID-19 before June 1, 2021. All persons with ME/CFS-like illness had significant impairment in physical, mental, emotional, social, and occupational functioning compared to persons without ME/CFS-like illness.
In a large, integrated health system, 1.67% of adults had ME/CFS-like illness and 14.12% of all persons with ME/CFS-like illness developed it after COVID-19. Though COVID-19 did not substantially increase ME/CFS-like illness in the KPNC population during the study time period, ME/CFS-like illness nevertheless affects a notable portion of this population and is consistent with estimates of ME/CFS prevalence in other populations. Additional attention is needed to improve awareness, diagnosis, and treatment of ME/CFS.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39292671</pmid><doi>10.1371/journal.pone.0309810</doi><tpages>e0309810</tpages><orcidid>https://orcid.org/0000-0001-8286-6593</orcidid><orcidid>https://orcid.org/0000-0003-1630-5733</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2024-09, Vol.19 (9), p.e0309810 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_3106664852 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adolescent Adult Adults Aged Biology and Life Sciences California California - epidemiology Care and treatment Chronic fatigue syndrome Confidence intervals Coronaviruses COVID-19 COVID-19 - epidemiology Cross-Sectional Studies Development and progression Diagnosis Disease control Diseases Electronic health records Encephalomyelitis Epidemics Ethnicity Fatigue Fatigue Syndrome, Chronic - epidemiology Fatigue Syndrome, Chronic - virology Female Health aspects Health maintenance organizations Health surveillance Humans Illnesses Infections Male Medical records Medical research Medicine and Health Sciences Medicine, Experimental Middle Aged Nucleic acids Pandemics Population studies Prevalence Research and Analysis Methods Respiratory diseases SARS-CoV-2 - isolation & purification Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Surveys Surveys and Questionnaires Viral diseases Young Adult |
| title | Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A36%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20COVID-19%20on%20myalgic%20encephalomyelitis/chronic%20fatigue%20syndrome-like%20illness%20prevalence:%20A%20cross-sectional%20survey&rft.jtitle=PloS%20one&rft.au=Wood,%20Mariah%20S&rft.aucorp=for%20STOP-ME/CFS%20and%20COVID-SELECT&rft.date=2024-09-18&rft.volume=19&rft.issue=9&rft.spage=e0309810&rft.pages=e0309810-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0309810&rft_dat=%3Cgale_plos_%3EA809114751%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3106664852&rft_id=info:pmid/39292671&rft_galeid=A809114751&rfr_iscdi=true |